Literature DB >> 26171669

Lessons learnt from the management of a case of Lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa.

Michael O Iroezindu1, Uche S Unigwe1, Celestine C Okwara1, Gladys A Ozoh1, Anne C Ndu2, Martin E Ohanu3, Ugochukwu O Nwoko1, Uwadiegwu W Okoroafor1, Esinulo Ejimudo4, Ekaete A Tobin5, Danny A Asogun5.   

Abstract

OBJECTIVE: To describe our experiences in the management of a case of Lassa fever (LF) and follow-up of nosocomial primary contacts during the 2014 Ebola outbreak in West Africa.
METHODS: Clinical management of the index case and infection control/surveillance activities for primary contacts are described. Laboratory confirmation was by Lassa virus-specific reverse-transcriptase PCR.
RESULTS: A 28-year-old man with a 10-day history of febrile illness was referred to a major tertiary hospital in south-east Nigeria from a city that previously experienced a LF outbreak and was recently affected by Ebola. On observation of haemorrhagic features, clinicians were at a crossroads. Diagnosis of LF was confirmed at a National Reference Centre. The patient died despite initiation of ribavirin therapy. Response activities identified 121 primary contacts comprising 78 (64.5%) hospital staff/interns, 19 (15.7%) medical students, 18 (14.9%) inpatients and 6 (5.0%) relatives. Their mean age was 32.8 ± 6.6 years, and 65.3% were women. Twenty (16.5%) had high-risk exposure and were offered ribavirin as post-exposure prophylaxis. No secondary case of LF occurred. Fatigue (43.8%) and dizziness (31.3%) were the commonest side effects of ribavirin.
CONCLUSIONS: Response activities contained nosocomial spread of LF, but challenges were experienced including lack of a purpose-built isolation facility, absence of local Lassa virus laboratory capacity, failure to use appropriate protective equipment and stigmatisation of contacts. A key lesson is that the weak health systems of Africa should be comprehensively strengthened; otherwise, we might win the Ebola battle but lose the one against less virulent infections for which effective treatment exists.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Ebola; Fiebre de Lassa; Lassa fever; contactos primarios; fièvre de Lassa; lecciones; lessons; leçons; premier contact; primary contact; surveillance; vigilancia; Ébola

Year:  2015        PMID: 26171669     DOI: 10.1111/tmi.12565

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  8 in total

1.  Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria.

Authors:  Samson E Isa; Attah Okwute; Kelly O Iraoyah; Shehu Y Nathan; Gomerep S Simji; Mark O Okolo; Joseph Anejo-Okopi; Daria Spicola; Daisy E Isa
Journal:  Niger Med J       Date:  2016 Jul-Aug

2.  Lessons Learnt from Epidemiological Investigation of Lassa Fever Outbreak in a Southwest State of Nigeria December 2015 to April 2016.

Authors:  Elvis Efe Isere; Akinola Ayoola Fatiregun; Olayinka Ilesanmi; Ibidolapo Ijarotimi; Beatrice Egube; Adewale Adejugbagbe; Gboyega Adekunle Famokun
Journal:  PLoS Curr       Date:  2018-06-29

Review 3.  Containment measures for emerging and re-emerging vector-borne and other infectious diseases of poverty in urban settings: a scoping review.

Authors:  Laurence Campeau; Stéphanie Degroote; Valery Ridde; Mabel Carabali; Kate Zinszer
Journal:  Infect Dis Poverty       Date:  2018-09-03       Impact factor: 4.520

Review 4.  Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.

Authors:  Morgan E Brisse; Hinh Ly
Journal:  Front Immunol       Date:  2019-03-13       Impact factor: 7.561

5.  A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks-results from the Lassa fever pilot.

Authors:  Louise Sigfrid; Catrin Moore; Alex P Salam; Nicola Maayan; Candyce Hamel; Chantelle Garritty; Vittoria Lutje; Brian Buckley; Karla Soares-Weiser; Rachel Marshall; Mike Clarke; Peter Horby
Journal:  BMC Med       Date:  2019-06-11       Impact factor: 8.775

6.  Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.

Authors:  Jingjing Jiang; Preeti Banglore; Kathleen A Cashman; Connie S Schmaljohn; Katherine Schultheis; Holly Pugh; Jacklyn Nguyen; Laurent M Humeau; Kate E Broderick; Stephanie J Ramos
Journal:  Hum Vaccin Immunother       Date:  2019-06-19       Impact factor: 3.452

7.  Lesson learned from the investigation and response of Lassa fever outbreak, Margibi County, Liberia, 2018: case report.

Authors:  Abyot Bekele Woyessa; Leroy Maximore; Darius Keller; John Dogba; Myer Pajibo; Kumblytee Johnson; Emmanuel Saydee; Julius Monday; Roland Tuopileyi; Nuha Mahmoud
Journal:  BMC Infect Dis       Date:  2019-07-11       Impact factor: 3.090

8.  Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Authors:  Laura Merson; Josephine Bourner; Sulaiman Jalloh; Astrid Erber; Alex Paddy Salam; Antoine Flahault; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2021-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.